Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates?

@article{Cannom2009InflammatoryBD,
  title={Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates?},
  author={Rebecca R Cannom and Andreas M. Kaiser and Glenn T Ault and Robert W. Beart and David A. Etzioni},
  journal={The American surgeon},
  year={2009},
  volume={75 10},
  pages={976-80}
}
The treatment costs for patients in the United States with inflammatory bowel disease (IBD) exceed 1.7 billion dollars/year. Infliximab, an antibody to tumor necrosis factor-alpha has been extensively used to treat IBD, with 390,000 IBD patients receiving the drug since its FDA approval in 1998. We sought to determine the impact of infliximab on population-based rates of hospitalizations and surgical care for patients with IBD in the United States. We used data from the Nationwide Inpatient… CONTINUE READING